<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pharmather Holdings Ltd — News on 6ix</title>
<link>https://6ix.com/company/pharmather-holdings-ltd</link>
<description>Latest news and press releases for Pharmather Holdings Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pharmather-holdings-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836835f78dffbe2df169427.webp</url>
<title>Pharmather Holdings Ltd</title>
<link>https://6ix.com/company/pharmather-holdings-ltd</link>
</image>
<item>
<title>PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-filing-of-us-patent-application-for-its-peptide-microneedle-patch-technology</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-filing-of-us-patent-application-for-its-peptide-microneedle-patch-technology</guid>
<pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
<description>Patent filing intended to strengthen PharmaTher's peptide formulation capabilities for PharmaPatch™ while complementing PatchPrint™ as part of the Company's broader microneedle patch development and commercialization strategyToronto, Ontario--(Newsfile Corp. - April 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/034,315 to the United States..</description>
</item>
<item>
<title>PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-introduces-patchprinttm-with-provisional-patent-filing-and-commercialization-strategy-for-microneedle-patches</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-introduces-patchprinttm-with-provisional-patent-filing-and-commercialization-strategy-for-microneedle-patches</guid>
<pubDate>Thu, 26 Mar 2026 12:00:00 GMT</pubDate>
<description>Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including peptide patches, branded wellness patches, manufacturing systems and commercial partnerships.Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it submitted a provisional...</description>
</item>
<item>
<title>PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-expands-pharmapatch-delivery-platform-into-therapeutic-peptides-for-the-us-market</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-expands-pharmapatch-delivery-platform-into-therapeutic-peptides-for-the-us-market</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides, today announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market, building on the Company's ketamine and psychedelics patch development achievements and its recent entry</description>
</item>
<item>
<title>PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-launches-strategic-initiative-pursue-142700122</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-launches-strategic-initiative-pursue-142700122</guid>
<pubDate>Mon, 02 Feb 2026 14:27:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization. Semaglutide is the active ingredient in Ozempic® and Wegovy®. The initiative builds on PharmaTher's demonstrated regulatory and partnering execution,...</description>
</item>
<item>
<title>PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-expands-pharmapatch-tm-platform-130000134</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-expands-pharmapatch-tm-platform-130000134</guid>
<pubDate>Wed, 14 Jan 2026 13:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for the potential treatment of obesity.PharmaTher's decision to enter...</description>
</item>
<item>
<title>PharmaTher CEO Publishes Letter to Shareholders</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-ceo-publishes-letter-shareholders-130000470</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-ceo-publishes-letter-shareholders-130000470</guid>
<pubDate>Fri, 02 Jan 2026 13:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders.Dear Shareholders,With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead.PharmaTher's strategy is..</description>
</item>
<item>
<title>PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-closes-sale-ketamine-anda-145300904</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-closes-sale-ketamine-anda-145300904</guid>
<pubDate>Tue, 02 Dec 2025 14:53:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company.At closing, PharmaTher</description>
</item>
<item>
<title>PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-advances-strategy-build-next-130000323</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-advances-strategy-build-next-130000323</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced that it has entered into an Exclusive Evaluation and Option-to-License Agreement (the "Agreement") with Oakwood Laboratories, LLC ("Oakwood") for the development and commercialization of Oakwood's patented long-acting</description>
</item>
<item>
<title>PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-applauds-fdas-commissioners-national-122600505</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-applauds-fdas-commissioners-national-122600505</guid>
<pubDate>Fri, 17 Oct 2025 12:26:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today applauds the U.S. Food and Drug Administration's ("FDA") announcement on October 16, 2025 of the first-ever recipients of the new Commissioner's National Priority Voucher ("CNPV") pilot program, which include "ketamine for domestic manufacturing of a...</description>
</item>
<item>
<title>PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-advances-phase-3-fda-120000864</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-advances-phase-3-fda-120000864</guid>
<pubDate>Thu, 16 Oct 2025 12:00:00 GMT</pubDate>
<description>Company preparing FDA meeting package to align on a single, well-controlled Phase 3 study under 505(b)(2); Pharma partner discussions ongoingToronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced that it has begun preparing its U.S. Food and Drug Administration ("FDA") briefing materials to discuss a</description>
</item>
<item>
<title>PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-ketaimine-tm-ai-120000629</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-ketaimine-tm-ai-120000629</guid>
<pubDate>Wed, 15 Oct 2025 12:00:00 GMT</pubDate>
<description>Expanding ketamine indications, fortifying IP, enabling earlier partnerships, and accelerating FDA pathways - underpinned by PharmaTher's Digital Health AI division, leveraging the Company's FDA-approved ketamine ANDA CMC and KetaVault(TM) data advantage.Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today..</description>
</item>
<item>
<title>PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-provides-ketamine-program-lid-120000945</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-provides-ketamine-program-lid-120000945</guid>
<pubDate>Wed, 08 Oct 2025 12:00:00 GMT</pubDate>
<description>Phase 3 program targeting a potential US$2.2B U.S. market opportunity505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and timeFDA-reviewed CMC package validated through prior ANDA approvalPatent coverage to 2036 for ketamine in Parkinson's and related motor disordersActive pharmaceutical partnering discussionsUpcoming catalysts (Q4 2025 - Q2 2026): FDA meeting, pivotal study readiness, pharma partnershipToronto, Ontario--(Newsfile Corp. - October 8, 2025) - PharmaTher.</description>
</item>
<item>
<title>PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-provides-corporate-ketamine-development-120000084</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-provides-corporate-ketamine-development-120000084</guid>
<pubDate>Thu, 02 Oct 2025 12:00:00 GMT</pubDate>
<description>TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a corporate update following its recently announced sale of the Company’s Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP (the “Ketamine ANDA”). The transaction was a strategic sale of a single generic ketamine</description>
</item>
<item>
<title>PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-sale-ketamine-anda-120000308</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-sale-ketamine-anda-120000308</guid>
<pubDate>Wed, 01 Oct 2025 12:00:00 GMT</pubDate>
<description>TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that it has entered into a definitive Asset Purchase Agreement (the “Agreement”) for the sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a well-established global pharmaceutical company specializ</description>
</item>
<item>
<title>PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-advances-ketamine-patch-non-120000028</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-advances-ketamine-patch-non-120000028</guid>
<pubDate>Wed, 27 Aug 2025 12:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - August 27, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, today announced the advancement of its ketamine transdermal patch as a next-generation, non-opioid pain relief solution, building on the recent FDA approval of its IV ketamine product (KETARx™)."With KETARx™ now FDA-approved, our next chapter is to expand...</description>
</item>
<item>
<title>PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-provides-corporate-following-fda-120000207</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-provides-corporate-following-fda-120000207</guid>
<pubDate>Tue, 26 Aug 2025 12:00:00 GMT</pubDate>
<description>Company advancing U.S. commercialization with FDA-approved ketamine and rare disorder NDA filingsTORONTO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a corporate update highlighting commercial readiness for ketamine (KETARx™) and an ambitious regulatory program aimed at advancing KETARx™ for rare disorde</description>
</item>
<item>
<title>PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-founder-ceo-issues-letter-120000793</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-founder-ceo-issues-letter-120000793</guid>
<pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio Chianelli, the Company's Founder, Chairman and Chief Executive Officer, has issued the following letter to shareholders.Dear Fellow Shareholders,Earlier this year, I wrote to you about the challenges we faced with our FDA Priority Orig</description>
</item>
<item>
<title>PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-founder-ceo-issues-letter-120000522</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-founder-ceo-issues-letter-120000522</guid>
<pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
<description>TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio Chianelli, the Company’s Founder, Chairman and Chief Executive Officer, has issued the following letter to shareholders. Dear Fellow Shareholders, Earlier this year, I wrote to you about the challenges we faced with our FDA Priority Original Abbre</description>
</item>
<item>
<title>PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-fda-approval-ketamine-134900964</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-fda-approval-ketamine-134900964</guid>
<pubDate>Mon, 11 Aug 2025 13:49:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that it received the U.S. Food and Drug Administration (FDA) approval for the Company's ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a</description>
</item>
<item>
<title>PharmaTher Announces FDA Approval of Ketamine (KETARx™)</title>
<link>https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-fda-approval-ketamine-132600801</link>
<guid isPermaLink="true">https://6ix.com/company/pharmather-holdings-ltd/news/pharmather-announces-fda-approval-ketamine-132600801</guid>
<pubDate>Mon, 11 Aug 2025 13:26:00 GMT</pubDate>
<description>TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved the Company’s ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achieve</description>
</item>
</channel>
</rss>